Antipsychotic medication and venous thrombosis

RENÉ THOMASSEN, JAN P. VANDENBROUCKE and FRITS R. ROENDEAAL

Background   In an autopsy series, 10 out of 27 deaths in which ‘idiopathic’ pulmonary emboli were discerned as the sole cause of death had occurred in psychiatric patients.

Aims   To investigate whether antipsychotic medication is a risk factor for venous thrombosis.

Method   A description of the 10 psychiatric patients was obtained from the pulmonary emboli autopsy reports. We carried out a brief historic overview of the literature. We re-analysed data from the Leiden Thrombophilia Study (LETS), a case–control study on patients with venous thrombosis.

Results   In the autopsy reports, five out of 10 psychiatric patients with fatal pulmonary embolism had confirmed use of antipsychotic drugs. After the application of chlorpromazine and its analogues a higher incidence of venous thrombosis in psychiatric patients was described in the German literature between 1953 and 1977. In the re-analysis of the LETS case–control study, four patients used antipsychotic drugs versus none in the control group. Recent epidemiological studies of good methodological quality have confirmed these findings.

Conclusions   Venous thrombosis appears to be associated with the use of antipsychotic drugs in psychiatric patients.

Declaration of interest   None.

In a study to investigate a genetic basis for fatal pulmonary embolism in autopsy reports at the Leiden University Medical Center, 10 out of 27 deaths in which pulmonary emboli were discerned as the sole cause of death and in which no other major underlying risk factor was present had occurred in psychiatric or psychogeriatric patients (Vandenbroucke et al, 1998). Inspired by this unanticipated finding, we searched the literature for studies on thrombosis in psychiatric patients. A number of papers, mostly in German literature between 1966 and 1984, reported an association between psychiatric illness and thrombosis, in particular pulmonary embolism. In 1997 this association received renewed attention in a study about mortality in people taking clozapine (Walker et al, 1997). In 2000, new studies reported a significantly increased risk of venous thrombosis in patients exposed to antipsychotic drugs (Hagg et al, 2000; Thomassen et al, 2000; Zornberg & Jick, 2000).

We present a comprehensive report of the 10 psychiatric patients from the Leiden autopsy reports, and give a brief historic overview of the literature dealing with venous thrombosis in psychiatry. We also present secondary analyses of a case–control study on risk factors for venous thrombosis, the Leiden Thrombophilia Study (LETS; Koster et al, 1993).

Methods

Autopsy records

At the Leiden University Medical Center, 14 000 autopsy records from 1970 until mid-1994 were reviewed to select those in which pulmonary embolism was the sole cause of death. Only 27 autopsies fulfilled this criterion. Ten of these autopsies had occurred in psychiatric patients (Vandenbroucke et al, 1998). In order to find a common characteristic other than the psychiatric illness, we reviewed the original autopsy reports of the 10 psychiatric patients in detail. The autopsy reports included additional information such as a brief history of the admission or a copy of the discharge letter. We looked at age, gender, psychiatric diagnosis, hospital admission time, medication use, and clues for immobilisation and somatic illness prior to the pulmonary embolism.

Historic literature overview

Based on our findings in the autopsy record study we searched Medline from 1960 to 1998 for material on the subject of psychiatry and venous thrombosis, specifically antipsychotic medication and pulmonary embolism.

Case–control study

Details about the methodology of the case–control study have been published earlier (Koster et al, 1993). In brief, from 1990 to 1993, 474 incident cases with a first episode of deep-vein thrombosis, in whom objective tests had confirmed the diagnoses, were selected from three anticoagulation clinics. In the Netherlands, anticoagulation clinics monitor coumarin treatment for virtually all patients diagnosed with venous thrombosis in well-defined geographic areas. The study was limited to outpatients. Psychiatric in-patients or general hospital in-patients who were in the hospital at the time of enrolment were excluded. The patients were asked to find a control subject of the same gender, about the same age, who was not a biological relative, had no history of thrombosis or malignant disorders and did not use coumarins. This population-based case–control study was used to estimate the risk of a first episode of deep-vein thrombosis in relation to several clotting factor abnormalities (Koster et al, 1993).

Participants were asked to report any medication use. Comorbidity and medical treatments were assessed. Risk factors for thrombosis such as oral contraceptive use, surgery, immobilisation and family history were evaluated extensively. For patients with a first episode of deep-vein thrombosis, medical reports on the admission and treatment were retrieved. Patients older than 70 years of age and patients with malignancies were excluded. Fifty-one patients declined participation and 19 patients were excluded because of psychiatric morbidity which would interfere with participation in the study (Koster et al, 1993).
In the current re-analysis we investigated the frequency of daily use from the available records. First, we investigated the patient and control groups for any daily use of antipsychotics, antidepressants and benzodiazepines (including the index year in which the first episode of deep-vein thrombosis occurred). Second, patients who report usage of these drugs in the same year as the index date of their first thrombosis were excluded to be certain that the medication was used prior to the first thrombosis. Third, we restricted the analyses to those patients with mono-therapeutic medication use, to rule out any interference with comedication and comorbid conditions. Whether patients with a first episode of deep-vein thrombosis used more medication in general, compared with the controls, was checked for other commonly used medications such as beta-blockers and antacids. Odds ratios and 95% confidence intervals were generated through Epi Info 6 (Centers for Disease Control and Prevention & World Health Organization, 1997).

RESULTS

Autopsy records

Among the 10 psychiatric patients there was a considerable diversity in psychiatric diagnosis and periods of admission. None of the patients had an acute psychotic episode prior to the pulmonary embolism. Five patients had used antipsychotic drugs. From the information we could extract from the autopsy reports this was the only common characteristic. Table 1 shows gender, age (mean and range) and presence of risk factors in comparison with the patients who did not use antipsychotic drugs (n=2) or for whom medication use was not reported (n=3). The five patients who had taken antipsychotic medication were younger than those who had not, and no risk factors for pulmonary embolism were present in any of them. Among the non-antipsychotic users, three patients had impaired mobility. We concluded that the younger age at first occurrence as well as the lack of immobilisation pointed to an association of antipsychotic drug use and venous thrombosis.

Historical literature overview

The discovery of the antipsychotic qualities of chlorpromazine in 1953 was soon followed by several case reports in the German literature of fatal pulmonary embolism related to its use (Brehmer & Ruckdeschel, 1953; Labhardt, 1954). A first case series, for the period 1954–1957, reported on 11 (3.3%) cases of venous thrombosis and pulmonary embolism in a group of 338 phenothiazine users, compared with one in a non-phenothiazine control group (Graham & Suchenwirth, 1959). In 1963, Mahmodian (1963) observed a three-fold increased risk of thrombosis in the period 1958–1961 in psychiatric and neurological patients compared with the years 1915–1922 (from 6% to 18% in males and 10% to 29% in females). In 1966, Lal et al. (1966) reported on consecutive autopsies on 357 psychiatric patients diagnosed mainly with schizophrenia and a chronic brain syndrome over the period 1961–1964. The prevalence of pulmonary embolism found in those autopsies was 10%, which was the same as in all autopsies in the general hospital population (Lal et al., 1966). However, the occurrence of pulmonary embolism in the general hospital population is known to be high; so, the comparability with a general hospital population in fact points to a high incidence. In a similar study of 343 autopsy reports of psychiatric patients, Kendell & Fodor (1969) found 98 (29%) cases of pulmonary embolism, which in 16% was associated with acute psychiatric symptoms. Scholz (1967) studied 37 psychiatric patients with a pulmonary embolism as the clinical cause of death. Twenty-two patients had used antipsychotic drugs. They were younger and in one-third of the cases there was no explanatory comorbidity. Ziegler (1977) studied 688 autopsy reports with pulmonary embolism as the sole cause of death. Twenty-seven (4%) had an underlying psychiatric disorder. Twelve suffered from schizophrenia and 15 had a depressive illness.

In a large observational study, Meier-Ewert et al. (1967) compared two groups between 1953 and 1963: 1092 patients with schizophrenia or depression taking chlorpromazine, amitriptyline or imipramine and a group of 1172 similar psychiatric patients who did not use antipsychotic or antidepressant medication. The frequency of thrombo-embolic complications in the medication group was 2.9% versus 0.59% in the control group. However, 22 of the 34 medication users with a thrombo-embolic complication showed medical comorbidity. An interesting observation was made in 1984: five women with schizophrenia, 33–38 years of age, suffered from deep-venous thrombosis after an acute psychotic phase. They all died from pulmonary embolism without any comorbidity (Hinderer et al., 1984). Apart from general papers dealing with mortality in psychiatric hospitals (Licht et al., 1993; Hewer et al., 1995), until recently this 1984 paper was the last published paper on the specific subject of venous thrombosis in psychiatric patients. However, the subject found new attention in a study of Walker et al. (1997) and Hagg et al. (2000).

Case-control analysis

Baseline characteristics of out-patients with a first episode of venous thrombosis (n=474) who used antipsychotic drugs, antidepressants or benzodiazepines and a matched control group (n=474) are reported in Table 2. A hip operation, heart valve disease, heart rhythm abnormalities and intravenous heroin use until 1 year prior to the first episode of deep-vein thrombosis was reported as comorbidity. Medication use concerning five different medication categories among patients with a first episode of deep-vein thrombosis (n=474) and the control group (n=474) is shown in Table 3. In this table the medication use is reported with increasing restrictiveness: first, all use; second, use restricted to the year preceding the venous thrombosis; third, use limited to monotherapy. Four patients used antipsychotic drugs compared with none in the control group. Their mean age was 42.8 years. One of these patients also used an antidepressant and a benzodiazepine. The antipsychotic drugs used were levomepromazine, fluphenazine (both phenothiazines) and haloperidol. Antidepressant use differed between subjects in the case and control

<table>
<thead>
<tr>
<th>Antipsychotic medication</th>
<th>Yes (n=5)</th>
<th>No (n=5)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>2</td>
<td>–</td>
</tr>
<tr>
<td>Female</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>51</td>
<td>61</td>
</tr>
<tr>
<td>Range</td>
<td>41–67</td>
<td>41–67</td>
</tr>
<tr>
<td>Risk factors</td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>5</td>
<td>2</td>
</tr>
<tr>
<td>Yes (immobilisation)</td>
<td>–</td>
<td>3</td>
</tr>
</tbody>
</table>

Table 1 Antipsychotic medication, gender, mean age and risk factors for thrombosis of psychiatric patients with pulmonary embolism as the sole cause of death (n=10)
groups and yielded an odds ratio of 2.3 (95% CI 0.6–10.6). Medication use in general, such as beta-blocking agents and antacids, did not differ between patients and controls.

### Discussion

**Autopsy series**

A review of the Leiden University Hospital autopsy records in which pulmonary embolism was the sole cause of death led to the unanticipated finding of a large number of psychiatric patients with antipsychotic drug use. The finding that about one in three patients with idiopathic fatal pulmonary embolism were referred from a psychiatric institute was surprising because on average over the past 10 years the referral rate of such patients in autopsies was only 5–10%. However, it cannot be excluded that selective factors leading to autopsy might have led to the large number of psychiatric patients in our series, as we discussed in our original report (Vandenbroucke et al., 1998). Because of this possible selection bias the hypothesis of antipsychotic drugs as a possible risk factor for deep-vein thrombosis was ‘data-driven’.

**Historical literature overview**

Predominantly German literature between 1953 and 1984 confirmed a high prevalence of thrombosis in psychiatric patients, also with an association with antipsychotic use. Unfortunately, specific information about the diagnoses, medication use and physical circumstances under which the thrombosis occurred were often missing.

**Case–control analysis**

Our findings in the re-analysis of the case–control study are compatible with the hypothesis of antipsychotic drugs as a possible risk factor for deep-vein thrombosis. Moreover, the original study excluded all in-patients, also psychiatric in-patients, so that our conclusions relate only to outpatient antipsychotic drug use. As the numbers are small, confidence intervals are wide. In consequence the results in themselves are not conclusive.

### Recent literature

Our results are in line with a 1992 publication reporting an impressive 17-fold increase in risk of myocardial infarction observed among young women using psychotropic drugs and also an almost three-fold increased risk of venous thrombo-embolism (Thorogood et al., 1992). A similar recent observation came from a study on mortality in clozapine users. Among current users of clozapine, 19 cases in 85,399 person-years of fatal pulmonary embolism were found. This risk was increased 5.2-fold when compared with the non-use of clozapine (Walker et al., 1997). Most recently, Zornberg & Jick (2000) studied a baseline population of 29,952 recipients of antipsychotic drugs. They found an odds ratio of 3.3 for high-potency antipsychotic drugs such as haloperidol and an odds ratio of

### Table 2

Baseline characteristics of out-patients using antipsychotic drugs, antidepressants or benzodiazepines in cases with a first episode of deep-vein thrombosis (n=474) and a control group (n=474) during a period including the index year

<table>
<thead>
<tr>
<th></th>
<th>Patients with deep-vein thrombosis</th>
<th>Control</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Antipsychotics</td>
<td>Antidepressants</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>2</td>
<td>5</td>
</tr>
<tr>
<td>Female</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>Mean age (years)</td>
<td>42.8</td>
<td>51.8</td>
</tr>
<tr>
<td>Risk factors</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smoking</td>
<td>1</td>
<td>4</td>
</tr>
<tr>
<td>Taking oral contraceptives</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Comorbidity</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>Family history</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Total</td>
<td>2</td>
<td>8</td>
</tr>
</tbody>
</table>

### Table 3

Out-patients with a first episode of deep-vein thrombosis (n=474) and a control group (n=474) using psychotropic drugs, beta-blockers and antacid monotherapetics during a period including the index year, excluding the index year and of monotherapy medication use only

<table>
<thead>
<tr>
<th>Medication</th>
<th>Including index year</th>
<th>Excluding index year</th>
<th>Monotherapy use excluding index year</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Case</td>
<td>Control</td>
<td>Odds ratio (95% CI)</td>
</tr>
<tr>
<td>Psychotropic drugs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antipsychotics</td>
<td>4</td>
<td>0</td>
<td>(0.7–∞)</td>
</tr>
<tr>
<td>Antidepressants</td>
<td>9</td>
<td>4</td>
<td>2.3 (0.6–10.2)</td>
</tr>
<tr>
<td>Benzodiazepines</td>
<td>28</td>
<td>7</td>
<td>4.2 (1.8–11.5)</td>
</tr>
<tr>
<td>Beta-blockers</td>
<td>25</td>
<td>20</td>
<td>1.3 (0.7–2.4)</td>
</tr>
<tr>
<td>Antacids</td>
<td>16</td>
<td>10</td>
<td>1.6 (0.7–3.9)</td>
</tr>
</tbody>
</table>

∞ denotes result of division by zero; ∞, not determined.
24.1 for low-potency antipsychotic drugs such as chlorpromazine.

**Biological mechanism**

The biological mechanism explaining the relation between antipsychotic drugs and venous thrombosis is unknown. Multiple hypotheses have been postulated. In the most recent publications of Zornberg & Jick (2000) and Hagg et al (2000) three possible mechanisms are discussed: antipsychotic drugs enhance aggregation of platelets; anti- cardiacin antibodies are associated with increased risk of thrombosis and their levels are raised in some patients using chlorpromazine; and venous stasis is exacerbated by sedation. An alternative explanation can be found in the article of Hindersin et al (1984); the acute psychotic phase is associated with an increase of adrenaline secretion, which enhances the coagulation mechanism.

Venous thrombosis appears to be associated with the use of antipsychotic drugs in psychiatric patients. Clinicians should be aware of this possible relation when patients using antipsychotic drugs have complaints such as chest pain or dyspnoea. However, it cannot be completely excluded that the findings on antipsychotic drugs are an expression of some other underlying risk factors of the disease itself. Also, the use of these drugs might predispose to venous thrombosis because of other medication effects such as sedation and immobilisation. Because of the clinical implications we conclude that the association between venous thrombosis and psychiatric illness is worthy of renewed investigation, with an emphasis on the mechanisms that might elucidate a direct effect of antipsychotic drugs.

**REFERENCES**


Antipsychotic medication and venous thrombosis
RENE THOMASSEN, JAN P. VANDENBROUCKE and FRITS R. ROSENAAL
Access the most recent version at DOI: 10.1192/bjp.179.1.63

References
This article cites 17 articles, 0 of which you can access for free at:
http://bjp.rcpsych.org/content/179/1/63#BIBL

Reprints/permissions
To obtain reprints or permission to reproduce material from this paper, please write to permissions@rcpsych.ac.uk

You can respond to this article at
/letters/submit/bjprcpsych;179/1/63

Downloaded from
http://bjp.rcpsych.org/ on April 14, 2017
Published by The Royal College of Psychiatrists